SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinical-stage ...
Summit Therapeutics Inc.'s HARMONi study met its PFS endpoint but failed to show statistically significant overall survival, casting doubt on U.S. FDA approval prospects. The FDA has signaled it ...
Lantheus may have been hoping that “statistically significant” phase 3 data for its radioligand therapy would make a splash at ESMO, but not everyone is impressed. The biotech used the European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results